Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis, Chris Skedgel

Research output: Contribution to journalArticle

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)361-365
Number of pages5
JournalPharmacoEconomics
Volume29
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • Antibodies
  • Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Chemotherapy
  • Cost-Benefit Analysis
  • Disease-Free Survival
  • Early Termination of Clinical Trials
  • Female
  • Humans
  • Randomized Controlled Trials as Topic

Cite this